

## GENERAL MEETING OF APRIL 28, 2020

### WRITTEN QUESTIONS

Written questions may be submitted to the Company, pursuant to the rules established by law, with respect to any General Meeting. In conformity with the legislation in force, an answer is deemed to have been given to a written question provided it has been displayed on the Company's website.

\* \* \*

On April 22, 2020, the Board received thirty-one written questions addressed by a counsel on behalf of Diameno Holding OÜ, an Estonian company registered in 2018 and from its corporate officer Mr. Kyrill Lapin. These questions relate to the Marinomed product (nasal solution) and a license agreement concluded between the Austrian biopharmaceutical company Marinomed Biotech AG and a third company from which Sanofi has acquired an activity.

The Company considers that the questions do not comply with the regulatory framework of the right for shareholders to ask written questions in accordance with Article L. 225-108 of the French Commercial Code and, in particular, do not form part of a process of participation in the social life of the Company. The questions also do not allow to clarify the vote of the shareholders on the proposed resolutions.

In addition, the Company may not comment on positions supposedly attributed to third parties or divulge elements that could impair confidentiality and business secrecy.

In this context, the Company is not in a position to publish such written questions nor respond to them in the context of this meeting.